Pathophysiological mechanisms and evidence-based evaluation of extremely early in-hospital initiation of PCSK9 inhibitors in acute myocardial infarction

Historically, lipid management in acute myocardial infarction (AMI) has predominantly followed a statin-based stepwise titration strategy, causing many patients to miss their target lipid levels during the critical early risk window. Deeper research revealed that under the stress of acute ischemia and inflammatory microenvironments in AMI, PCSK9 exhibits a specific "extremely early burst", which impairs low-density lipoprotein cholesterol (LDL-C) clearance and directly drives pro-inflammatory macrophage polarization, endothelial barrier disruption, and microthrombosis through lipid-independent pathways. PCSK9 inhibitors achieve a dual blockade of this malignant pathological cascade by exerting strong lipid-dependent effects of lowering LDL-C and non-lipid pleiotropic effects of anti-inflammation and microcirculation protection. Recent clinical trials, including EVOPACS and EPIC-STEMI, substantiate that the extremely early in-hospital initiation of PCSK9 inhibitors (within 0-72 h of onset or periprocedurally during percutaneous coronary intervention) manifests a highly favorable safety profile concomitant with expedited lipid target attainment. Imaging studies, such as PACMAN-AMI, further demonstrated that early treatment can rapidly stabilize and promote the regression of vulnerable plaques, providing preliminary evidence that this strategy may reduce the short-term risk of recurrent cardiovascular events. Consequently, lipid-lowering pharmacotherapy is transitioning into a paradigm of "extremely early in-hospital initiation," effectively transcending conventional temporal therapeutic limitations. This review aims to systematically elucidate the stress-induced upregulation and pathophysiological mechanisms of PCSK9 within the acute AMI microenvironment, detail the dual interception mechanisms of PCSK9 inhibitors, and synthesize the clinical evidence base substantiating extremely early initiation over conventional therapeutic algorithms.

Authors

Institutions

Publication Details

Journal
Vessel Plus
Published
2026-11-17
DOI
https://doi.org/10.20517/2574-1209.2026.63
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pathophysiological mechanisms and evidence-based evaluation of extremely early in-hospital initiation of PCSK9 inhibitors in acute myocardial infarction

Gang Pan, Yujie Yan, Shihao Huang
2 links
Vessel Plus
Lipoproteins and Cardiovascular Health
article

Pathophysiological mechanisms and evidence-based evaluation of extremely early in-hospital initiation of PCSK9 inhibitors in acute myocardial infarction

Gang Pan, Yujie Yan, Shihao Huang
article en

Abstract

Historically, lipid management in acute myocardial infarction (AMI) has predominantly followed a statin-based stepwise titration strategy, causing many patients to miss their target lipid levels during the critical early risk window. Deeper research revealed that under the stress of acute ischemia and inflammatory microenvironments in AMI, PCSK9 exhibits a specific "extremely early burst", which impairs low-density lipoprotein cholesterol (LDL-C) clearance and directly drives pro-inflammatory macrophage polarization, endothelial barrier disruption, and microthrombosis through lipid-independent pathways. PCSK9 inhibitors achieve a dual blockade of this malignant pathological cascade by exerting strong lipid-dependent effects of lowering LDL-C and non-lipid pleiotropic effects of anti-inflammation and microcirculation protection. Recent clinical trials, including EVOPACS and EPIC-STEMI, substantiate that the extremely early in-hospital initiation of PCSK9 inhibitors (within 0-72 h of onset or periprocedurally during percutaneous coronary intervention) manifests a highly favorable safety profile concomitant with expedited lipid target attainment. Imaging studies, such as PACMAN-AMI, further demonstrated that early treatment can rapidly stabilize and promote the regression of vulnerable plaques, providing preliminary evidence that this strategy may reduce the short-term risk of recurrent cardiovascular events. Consequently, lipid-lowering pharmacotherapy is transitioning into a paradigm of "extremely early in-hospital initiation," effectively transcending conventional temporal therapeutic limitations. This review aims to systematically elucidate the stress-induced upregulation and pathophysiological mechanisms of PCSK9 within the acute AMI microenvironment, detail the dual interception mechanisms of PCSK9 inhibitors, and synthesize the clinical evidence base substantiating extremely early initiation over conventional therapeutic algorithms.

Vessel Plus
Jishou University (CN), Shanghai University of Traditional Chinese Medicine (CN), Yueyang Second People's Hospital (CN), Yueyang Hospital (CN)
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon